Alkermes Inc. plc - ALKS STOCK NEWS

Alkermes announced presentations at two key scientific conferences, showcasing research on LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil), and ALKS 2680. At the 37th Annual Psych Congress and the 2024 Neuroscience Education Institute Congress, Alkermes presented 12 posters, including a study on healthcare resource utilization in patients with schizophrenia and bipolar I disorder after LYBALVI initiation. The study revealed significant reductions in inpatient admissions and emergency department visits. Limitations include potential data omissions and coding errors. Additionally, safety and efficacy data from a phase 1b study of ALKS 2680 in narcolepsy were presented.

Alkermes (ALKS) reported strong Q3 2024 financial results with total revenues of $378.1 million. Net sales of proprietary products grew 18% year-over-year, with GAAP net income from continuing operations at $92.8 million. Key product performance includes LYBALVI revenues of $74.7 million (47% growth), ARISTADA at $84.7 million, and VIVITROL at $113.7 million (14% growth). The company maintains its 2024 financial guidance and continues to advance its pipeline, particularly ALKS 2680, its orexin 2 receptor agonist for narcolepsy treatment. During Q3, Alkermes repurchased approximately 4.4 million shares for $115.6 million, with $200 million remaining in the program.

Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast presentation on Thursday, October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results. The event will be accessible via the Investors section of Alkermes' website, with a webcast player and accompanying slides available. Participants can join the conference call by dialing +1 877 407 2988 (U.S. callers) or +1 201 389 0923 (international callers).

Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia.

Alkermes plc (Nasdaq: ALKS) has announced an investor event scheduled for October 9, 2024, at 10:00 a.m. EDT in Waltham, Mass. The event will focus on reviewing the company's orexin portfolio and development strategy. It will feature presentations by Alkermes' Research & Development team, followed by a clinician and thought leader panel discussion and a Q&A session.

The event will be accessible virtually via webcast, with registration available on the Investors section of Alkermes' website. A replay will be archived for 30 days following the presentation. Alkermes is a global biopharmaceutical company specializing in neuroscience, with a portfolio of commercial products for various mental health conditions and a pipeline of candidates for neurological disorders, including narcolepsy.

Alkermes plc (Nasdaq: ALKS) announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at Sleep Europe 2024. ALKS 2680 is an investigational, oral, selective orexin 2 receptor agonist for narcolepsy treatment. The company will share data from NT2 (n=9) and IH (n=8) patient cohorts, where ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo.

Alkermes will also present posters on the study design for ongoing phase 2 studies, Vibrance-1 and Vibrance-2, evaluating ALKS 2680 in narcolepsy type 1 and type 2 patients. The phase 1b study results support further clinical evaluation of ALKS 2680 as a potential treatment for sleep disorders with and without known orexin deficiency.

Alkermes plc (Nasdaq: ALKS) announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference. Management will engage in a fireside chat presentation on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT. A live webcast will be available on the company's website under the Investors tab and archived for 14 days.

Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. Their portfolio includes proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes has additional facilities in Massachusetts and Ohio.

Alkermes plc (Nasdaq: ALKS) has announced the launch of its 7th Annual Alkermes Pathways Research Awards® program, set to begin accepting applications on Sept. 20, 2024. This competitive grant program offers individual grants of up to $100,000 per project to support early-career investigators researching schizophrenia or bipolar disorder. The application period runs through Nov. 30, 2024.

Since its inception in 2018, the program has provided approximately $2.5 million in funding to 25 researchers across the United States. Eligible applicants must be M.D.s, Ph.D.s, or equivalent, within five years of their initial academic appointment or current post-doctoral fellows affiliated with a U.S. medical or research institution. An independent review committee will evaluate applications.

Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company specializing in neuroscience, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat presentation on Wednesday, Sept. 4, 2024, at 2:35 p.m. EDT. Investors can access the live webcast on Alkermes' website under the Investors tab, where it will remain archived for 14 days.

Alkermes focuses on developing innovative medicines for neurological disorders, with a portfolio of commercial products treating conditions such as alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for various neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes maintains a corporate office and research center in Massachusetts and a manufacturing facility in Ohio.

Alkermes plc (Nasdaq: ALKS) has initiated the Vibrance-2 study, a phase 2 clinical trial evaluating ALKS 2680 for the treatment of narcolepsy type 2 (NT2). ALKS 2680 is a novel, oral, selective orexin 2 receptor agonist being developed as a once-daily treatment for narcolepsy. The study will assess the safety and efficacy of ALKS 2680 compared to placebo in adults with NT2.

The trial will enroll approximately 80 patients across sites in the U.S., Australia, and Europe. Participants will receive one of three doses of ALKS 2680 (10 mg, 14 mg, or 18 mg) or placebo once-daily for eight weeks. The primary endpoint will measure changes in sleepiness using the maintenance of wakefulness test (MWT).